Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial.
A late-stage trial of a drug developed by Boehringer Ingelheim and Zealand Pharma resulted in an average 16.6% weight loss.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
See this on the live map
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
Hubs
Briefings
More story pages
US doctor exposed to Ebola to be hospitalized in Czech Republic
A US doctor who came into contact with an Ebola patient will be hospitalized in the Czech Republic.
Ebola deaths rise in DR Congo as WHO warns of further increase
More people have died in the ongoing Ebola outbreak in the Democratic Republic of Congo, with the World Health Organization warning that the numbers will continue to rise.
Russian AIDS specialist Vadim Pokrovsky dies at 83. Led research for 40 years.
Russian AIDS specialist Vadim Pokrovsky dies. Led research for 40 years, authored 300+ works. Aged 83.
Europe weighs response to Ebola outbreak: airport screenings, flight cancellations
Europe considers responses to the latest Ebola outbreak, including airport screenings and flight cancellations.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.